Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Buy" from Brokerages

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has been given an average rating of "Buy" by the ten ratings firms that are currently covering the company, Marketbeat reports. Nine analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $50.88.

A number of equities research analysts have commented on CRBP shares. Wedbush reiterated an "outperform" rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a report on Wednesday, March 12th. Jefferies Financial Group lowered their target price on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Oppenheimer lowered their price target on Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. B. Riley reaffirmed a "buy" rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, May 7th. Finally, HC Wainwright decreased their price target on Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday, May 7th.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CRBP. Wells Fargo & Company MN lifted its holdings in Corbus Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 2,195 shares during the last quarter. Deutsche Bank AG boosted its holdings in Corbus Pharmaceuticals by 46.8% during the fourth quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company's stock worth $97,000 after buying an additional 2,616 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Corbus Pharmaceuticals during the 4th quarter worth $101,000. Two Sigma Advisers LP purchased a new position in Corbus Pharmaceuticals in the 4th quarter worth about $130,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Corbus Pharmaceuticals in the fourth quarter worth approximately $323,000. Institutional investors own 64.64% of the company's stock.

Corbus Pharmaceuticals Stock Down 1.8%

NASDAQ:CRBP opened at $7.61 on Monday. The firm's fifty day simple moving average is $7.75 and its 200-day simple moving average is $8.32. The stock has a market cap of $93.12 million, a PE ratio of -1.80 and a beta of 3.05. Corbus Pharmaceuticals has a fifty-two week low of $4.64 and a fifty-two week high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.13). Equities analysts anticipate that Corbus Pharmaceuticals will post -4.23 earnings per share for the current year.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.